In a report released today, Jack Meehan from Barclays maintained a Buy rating on Laboratory (LH), with a price target of $188.00. The company’s shares closed last Monday at $133.99.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 2.3% and a 56.6% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and Myriad Genetics.
Laboratory has an analyst consensus of Moderate Buy, with a price target consensus of $205.56.
See today’s analyst top recommended stocks >>
The company has a one-year high of $196.36 and a one-year low of $98.02. Currently, Laboratory has an average volume of 931.5K.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LH in relation to earlier this year. Last month, Jean-Luc Belingard, a Director at LH sold 26,479 shares for a total of $5,024,655.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment involves in providing drug development solutions, to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.
